ApoA-I mimetic peptides may prevent atherosclerosis by targeting unsaturated lysophosphatidic acid in the gut.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for gut LPA-targeted atheroprevention; leaves open clinical translation of ApoA-I mimetics.
“the ability of the apoA-I mimetic peptides (as demonstrated by 6F) to modulate formation or block activity of unsaturated lysophosphatidic acid in the gut appears to the relevant mechanism of action for atheroprevention.”Submitted: 5 August 2015; Accepted: 14 August 2015; Online: 23 November 2015
No takes yet. Share an insight, caveat, or question.
Geoffrey D. Wool (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: